New 9-Month pill regimen could tackle Drug-Resistant TB
NCT ID NCT07268664
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests a 9-month, all-oral combination of four drugs (BLMZ) for people aged 12 and older with rifampicin-resistant tuberculosis. The goal is to see if this shorter regimen leads to a cure without the need for injections. Participants take the pills daily or weekly and are followed for 24 months to check for safety and effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BLMZ regimen (Bedaquiline, Linezolid, Moxifloxacin/Levofloxacin, Pyrazinamide)
What this could lead to
If successful, this could provide a shorter, all-oral treatment option for rifampicin-resistant tuberculosis, potentially improving cure rates and reducing treatment burden.
What could go wrong
This is a single-arm trial with no comparison group, so results are compared to historical data. The regimen may cause side effects like nerve damage or liver issues, and it may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center of Disease Prevention and Control in Kashi Area
Kashgar, Xinjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hetian Prefecture Infectious Diseases Hospital
Hetian, Xinjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Third People's Hospital in Aksou
Aksu, Xinjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••